Coherus BioSciences (CHRS)
(Real Time Quote from BATS)
$1.47 USD
0.00 (0.00%)
Updated Dec 26, 2024 03:08 PM ET
2-Buy of 5 2
C Value F Growth B Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CHRS 1.47 0.00(0.00%)
Will CHRS be a Portfolio Killer in December?
Zacks Investment Research is releasing its prediction for CHRS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CHRS
Here's Why You Should Add Dr. Reddy's Stock to Your Portfolio
RDY Launches Loqtorzi Biosimilar in India for Nasopharyngeal Carcinoma
CHRS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Coherus BioSciences (CHRS) Reports Q3 Loss, Tops Revenue Estimates
Acadia Healthcare (ACHC) Beats Q3 Earnings Estimates
Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates
Other News for CHRS
Coherus Biosciences to present final Phase 2 casdozokitug combination data
Coherus Biosciences to present final Phase 2 casdozokitug combination data
Coherus BioSciences: Shedding Pegfilgrastim To Fuel Ongoing Development
Biotech Alert: Searches spiking for these stocks today
Biotech Alert: Searches spiking for these stocks today